Tiziana Life Sciences Plc Reports Additional Positive Phase 2a Clinical Study Results For Milciclib

Tiziana Life Sciences Plc (AIM: TILS), has announced an additional positive Phase 2a clinical study results, which was conducted to evaluate the safety, tolerability and anti-tumor activity of Milciclib in Sorafenib-resistant patients

The data from the study exhibited the impressive clinical activity of Milciclib monotherapy in patients with advanced Sorafenib-resistant or intolerant patients with unresectable or metastatic hepatocellular carcinoma.

On 4th September 2019, at the time of writing, GMT 08:13 AM, TILS shares were trading at GBX 60.00, up by 12.00 points or 25.00% against the previous day closing price.

Facebook Comments